← FDA DRUG APPROVALS

FDA ANDA · ANDA215942

CABOZANTINIB

Sponsor: TEVA PHARMS INC

APPLICATION
ANDA215942
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CABOZANTINIBPrescription
CABOZANTINIB 40MG · TABLET · ORAL
CABOZANTINIBPrescription
CABOZANTINIB 60MG · TABLET · ORAL
CABOZANTINIBPrescription
CABOZANTINIB 20MG · TABLET · ORAL

Approval history

2022-10-27UNKNOWN · Original · standardTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →